Dannex Ayrton Starwin (XGHA:DASPHARMA) Research & Development: GHS Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XGHA:DASPHARMA Dannex Ayrton Starwin PLC XGHA:DASPHARMA
4 GF Score
Price GHS0.44
! 1 Warning Sign
View Full Analysis

What is Dannex Ayrton Starwin Research & Development?

Dannex Ayrton Starwin XGHA:DASPHARMA 4 Research & Development is GHS Mil as of . 20. GuruFocus rates XGHA:DASPHARMA with a GF Score™ of 4/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dannex Ayrton Starwin's Research & Development for the six months ended in . 20 was GHS0.00 Mil. Dannex Ayrton Starwin does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in . 20.

Dannex Ayrton Starwin  (XGHA:DASPHARMA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Dannex Ayrton Starwin Research & Development Related Terms

Dannex Ayrton Starwin Research & Development Historical Data

* Premium members only.

The historical data trend for Dannex Ayrton Starwin's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dannex Ayrton Starwin Research & Development Chart

Dannex Ayrton Starwin Annual Data
Trend
Research & Development

Dannex Ayrton Starwin Semi-Annual Data
Research & Development
XGHA:DASPHARMA
4GF Score
Dannex Ayrton Starwin PLC XGHA:DASPHARMA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dannex Ayrton Starwin Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of GHS Mil mean?
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a Research & Development of GHS Mil as of . 20. Research and development expense is the total cost for research and development activities. View historical data on Dannex Ayrton Starwin and its competitors.
Is Dannex Ayrton Starwin's Research & Development too high?
Dannex Ayrton Starwin's current Research & Development is GHS Mil. Overall, Dannex Ayrton Starwin has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Dannex Ayrton Starwin's Research & Development compare to ?
Dannex Ayrton Starwin's Research & Development of GHS Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dannex Ayrton Starwin and its competitors. Dannex Ayrton Starwin's current Research & Development is GHS Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dannex Ayrton Starwin stock overvalued right now?
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a current Research & Development of GHS Mil. The current Research & Development is GHS Mil. Dannex Ayrton Starwin's overall GF Score™ is 4/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dannex Ayrton Starwin (XGHA:DASPHARMA), the current Research & Development is GHS Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dannex Ayrton Starwin Business Description

Comparable Companies
Address No. 5 Dadeban Road, Ring Road North, North Industrial Area, Accra, GHA
Dannex Ayrton Starwin PLC is a pharmaceutical company. The company offers a product range that includes tablets, capsules, liquids syrups and suspensions, powders, ointments, and chemicals. It also manufactures and distributes Vitamin C.
4GF Score

Get the complete analysis for XGHA:DASPHARMA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

GHS0.44
Price